Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Medicure reported Q1 2026 revenue of $7.9 million, a 45% increase year-over-year, driven by growth in ZYPITAMAG sales and contributions from recently acquired pharmacies. The company posted a net loss of $406,000 ($0.04 per share), improved from a $694,000 loss in the prior year, with adjusted EBITDA rising to $280,000 from $28,000.
Key figures
- Revenue
- 7947000
- Revenue Yoy
- 45%
- Net loss
- 406000
- Rd expense
- 855000
- Adjusted ebitda
- 280000
- Aggrastat revenue
- 979000
- Zypitamag revenue
- 2300000
- Cash and equivalents
- 1542000
- Pharmacy segment revenue
- 5700000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.